David Melamed, PhD

David earned a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. This work helped to redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.

At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.

Articles by David Melamed, PhD

MYELOMA

New Nirogacestat Combos to Enter Myeloma Trials, SpringWorks Says

SpringWorks Therapeutics announced new collaborations with two companies, Pfizer and Janssen, to investigate its oral therapy candidate nirogacestat…

MYELOMA

Loss of Specific Gene May Help Drive Myeloma Progression, Study Finds

One of the most common genomic defects in multiple myeloma patients is the loss of one copy of chromosome 13,…

MYELOMA

Phase 1/2 Trial of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma to Open Soon

A clinical trial is soon to begin testing Precision BioSciences‘s new CAR T-cell therapy candidate, PBCAR269A, in people with relapsed…

MYELOMA

Advancing Novel Cell Therapy for Myeloma and Multiple Cancers Goal of New Partnership

A recent partnership between Indapta Therapeutics and Lonza is advancing the development of an off-the-shelf cell therapy designed to treat…

MYELOMA

NexImmune to Initiate Phase 1/2 Trial of NEXI-002 Cell Therapy for RRMM Patients

NexImmune will soon initiate a Phase 1/2 trial evaluating its cell therapy NEXI-002 in people with multiple…